Overall verdict
Buy
6.9/10
1-year performance
+39.57%
Score breakdown
Up 39.6% over 1 year, 52% of the 52-week range.
Strongest: Valuation 8.6/10. Weakest: Financial strength 1.4/10.
8 analysts, target +0.2% vs the price.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Javier Rodriguez
Founded
1994
Employees
78 000
Revenue / employee
174 911 USD
Next earnings
October 30, 2026 (estimated)
Institutional holders
- Berkshire Hathaway Inc43.91%
- BlackRock, Inc.3.74%
- VANGUARD CAPITAL MANAGEMENT LLC3.19%
- MORGAN STANLEY2.44%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.09%
- STATE STREET CORP2.01%
- Invesco Ltd.1.84%
- DIMENSIONAL FUND ADVISORS LP1.73%
- NEUBERGER BERMAN GROUP LLC1.41%
- Other institutions27.24%
- Rest of the register10.40%
625 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
247.49 USD
52-week low
101.00 USD
1-year performance
39.57%
Rising
Year-to-date performance
61.10%
Rising
Drawdown
-28.22%
Marked drawdown
Position in the 52-week range
52% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.6 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| DaVita | 78 130 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.6 times as much as the world ETF.
- Worst fall:-49 % between February 2025 and January 2026. 10,000 € placed at the top fell to 5 117 €. The world ETF, at worst: -34 %. Back to its high in 5 months.
DaVita kept pace with the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- DaVita: 78 130 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 362.38 USD - 455.29 USD (2 methods agree)
The price implies growth of -8.59% per year; the company grows at 8.29%.
Gross margin 27.3%, net margin 5.9%, ROIC 6.9%, ROE -149.4%.
Net margin
5.87%
Exceptional
Sector 3.21%|S&P 12.97%
Gross margin
27.29%
Fair
Return on equity (ROE)
-149.37%
Negative
Sector 7.20%|S&P 16.52%
Return on invested capital (ROIC)
6.88%
Exceptional
Free cash flow margin (FCF)
11.49%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.96x
High
Margin stability
1.9 pts
Very steady
Revenue to net income
Growth
7.7/10Revenue up 5.2% over 1 year, 3.4% a year over 5, EPS 8.3% a year over 5.
Revenue (trailing 12 months)
14.0Md USD
Revenue growth (1y)
5.17%
Moderate
Revenue growth (3y)
17.51%
Solid
EPS growth (1y)
55.84%
Hyper-growth
EPS CAGR (5y)
8.29%
Fair
EPS revisions (3 months)
-0.49%
Revised down
Valuation
8.6/10P/E 15.0x, forward P/E 12.2x, EV/EBITDA 7.6x, PEG 1.81. The multiple sits in the 79th percentile of its own 5-year history.
P/E (TTM)
15.0x
Cheap
Sector 30.9x|S&P 23.0x
Forward P/E
12.2x
Cheap
EV / EBITDA
7.6x
Cheap
Sector 13.1x|S&P 14.5x
PEG
1.81
Expensive
Sector 0.75|S&P 0.86
Fair value (reverse DCF)
401.16 USD
Deeply undervalued
P/E vs its own 5-year history
among the 21% highest valuations
Pricier than usual
Market cap
11.7Md USD
Financial strength
1.4/10Cash covers 5.8% of the debt, net debt/EBITDA 4.5x.
Net debt / EBITDA
4.5x
Stretched
Gearing (net debt / equity)
1170.49%
Stretched
Cash
772M USD
Cash / market cap
6.61%
Tight
Cash / total debt
5.76%
Stretched
Interest coverage
3.8x
Tight
Net debt
12.6Md USD
Equity
1.1Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 174.67 USD
- MM20182.38
- MM50196.41
- MM200168.34
- RSI 1437.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.07%
200-day average slope, 3 months
+17.02%
50-day average slope, 1 month
-7.89%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
2.21 % per day
Volatility change
-12.28%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 14.57 (5) | 14.77 (7) | 14 158 (7) | 2 912 (7) | 940 (4) |
| 2027 | 16.99 (5) | 17.14 (8) | 14 638 (7) | 2 986 (7) | 1 009 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HNGE | 7.2 | 6.6 | 7.4Md USD | 71.1x | 14.8 % | 53.0 % | 29.3 % | -3.8x | 3.8 % | 55.7 % | ||
| 2 | CI | 7.0 | 7.1 | 70.9Md USD | 11.1x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -8.0 % | ||
| 3 | DVA | 6.9 | 6.8 | 11.7Md USD | 15.0x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 39.6 % | ||
| 4 | LH | 6.7 | 5.9 | 24.7Md USD | 25.1x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 10.4 % | ||
| 5 | CVS | 6.6 | 5.8 | 110Md USD | 22.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 10.9 % | ||
| 6 | DGX | 6.5 | 5.8 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 7 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 8 | FME | 5.3 | 6.7 | 12.0Md USD | 11.8x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -10.0 % | ||
| 9 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % |
